The Lund University spinout, which is working on diagnostics technology for applications in oncology, will use the proceeds to pursue a recruitment drive.
Saga Diagnostics, a Sweden-based oncological diagnostics spinout from Lund University, has secured €1m ($1.2m) in a seed round featuring LU Holding, the university’s investment arm.
Other investors included Torna Kapital and the philanthropic Gunnar Nilsson Cancer Foundation, as well as angel investors Christer Fåhraeus and Simon Fredriksson.
Saga Diagnostics offers molecular genetics-based tests marketed as an efficient and sensitive diagnostic evaluation of cancer. The technology, sold to industry and academic researchers, sifts out tumour-derived DNA strands, known as ctDNA, from…
